Nuformix Reports Results from Novel Pre-Clinical Trial in IPF for NXP002 Programme

Cambridge, UK - 3rd December 2018

Nuformix, the pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs, announces results from the completion of its innovative pre-clinical trial for its NXP002 fibrosis programme in human idiopathic pulmonary fibrosis (‘IPF’) against standard of care.

 

Download News

Back to all News